Home/Pipeline/XmAb®819

XmAb®819

Renal Cell Carcinoma

Phase 1Active

Key Facts

Indication

Renal Cell Carcinoma

Phase

Phase 1

Status

Active

Company

Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Infectious Disease

Other Renal Cell Carcinoma Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
CB-839 (Telaglenastat)	Calithera Biosciences	Phase 2	Discontinued
XS008 (axitinib)	Xspray Pharma	Preclinical/Development	Disclosed, development ongoing
CDK7 allosteric inhibitor	Acellera	Pre-clinical	Early Hit
Precision Oncology - RCC	ReviveMed	Discovery	Active
Lenvatinib (LENVIMA)	Eisai	Regulatory Review	Application Submitted in Japan for combo with belzutifan
Cabozantinib	Exelixis	Phase 3	Active
Zanzalintinib (XL092)	Exelixis	Phase 3	Active
Casdatifan (AB521)	Arcus Biosciences	Phase 3	Enrolling